Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Justification:
Keloid scars are a major medical and cosmetic problem, especially in darker skin types that predominate in Mexico. It is estimated that hypertrophic scars affecting from 1.5 to 4.5% of the general population. However, the exact prevalence is unknown but studies show that going from 32 to 67%. And there are studies documenting that this prevalence is higher in Hispanic and black individuals and in the pediatric population.
Keloid scars can become highly symptomatic disfiguring and which affects the quality of life of patients and their self-esteem.Problem Statement:
Is silicone gel solutions superoxidation with equal or better than the gel 8% pirfenidone to treat keloids and hypertrophic scars?
Goal:
To evaluate the efficacy of a silicone gel-oxidation with solutions compared to a gel containing 8% pirfenidone.
Hypothesis:
If the silicone gel solutions superoxidation is equal or better than gel 8% pirfenidone to treat keloids and hypertrophic scars, then the reduction in the ECV and the EVA will be similar in the first group than the second.
Design:
Comparative, observer blind, experimental and prospective study.
This is a comparative, non-inferiority, experimental, prospective, longitudinal pilot study with blind evaluator, in patients with keloid or hypertrophic scars. Twenty patients per group randomly assigned to receive identical tubes of either a silicone-based gel with superoxidized water, or an 8% pirfenidone gel. Follow-up was scheduled at 2, 4, 8, 12, and 16 weeks recording the location, mechanism of the scar, time of evolution, skin phototype, accompanying symptoms, Dermatology Life Quality Index, and validated scar assessment tools (Patient and Observer Scar Assessment Scale, Vancouver Scar Scale, and the Analog Visual Scale for Keloids).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Topical Silicone Gel | Active Comparator | A gel containing silicone |
|
| Topical Pirfenidone Gel | Active Comparator | A gel containing pirfenidone |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| pirfenidone 8% gel | Drug | topic aplication |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Dermatology Life Quality Index Score | A life quality index for dermatological conditions | 3 months |
| Patient and Observer Scar Assessment Scale Score | A validated scale (POSAS and OSAS) to assess relevant clinical characteristics of scars. | 3 months |
| Vancouver Scar Scale | A validated scar scale | 3 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jose Contreras-Ruiz | Hospital General Dr Manuel Gea Gonzalez | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital General Manuel Gea González | Mexico City | Mexico City | 01710 | Mexico |
Not provided
| ID | Term |
|---|---|
| D002921 | Cicatrix |
| D007627 | Keloid |
| D017439 | Cicatrix, Hypertrophic |
| ID | Term |
|---|---|
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003095 | Collagen Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C093844 | pirfenidone |
| D005782 | Gels |
| ID | Term |
|---|---|
| D003102 | Colloids |
| D045424 | Complex Mixtures |
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
Not provided
Not provided
Not provided
Tubes containg both active treatments were identical. Outcomes assessor was blinded to treatment arm.
| silicon gel | Drug | topic aplication |
|
|
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |